JorgeAP
@ap_jalonsop
Neurologist focused on neuromuscular diseases and clinical and translational research.
You might like
🚀 Thrilled to share our new paper in Annals of Neurology! @ANA_journals We report a new phenotype linked to DARS2, establishing it as a causal gene for axonal neuropathy, a step forward in neuromuscular genetics 🧬 A long journey, but totally worth it! 🔗 doi.org/10.1002/ana.78…
Biallelic Variants in the DARS2 Gene as a Novel Cause of Axonal Charcot–Marie–Tooth Disease #RareDisease #Genetics onlinelibrary.wiley.com/doi/10.1002/an…
Whole-exome sequencing identifies TRIM72 as a candidate gene for autosomal recessive limb-girdle muscular dystrophy #RareDisease #Genetics humgenomics.biomedcentral.com/articles/10.11…
🚨New PhD studentship opportunity: "Modelling of Disease Progression in Facioscapulohumeral muscular dystrophy (FSHD) through Multi-Omic and Clinical Data Integration". ncl.ac.uk/postgraduate/f…
This is a very cool study from Profs. Lunn and Rinaldi’s groups. Periaxin is a promising biomarker of peripheral nerve demyelination. Larger studies are needed, but it appears to be the “Nfl” of the Schwann cells, as it was normal in MS patients. academic.oup.com/brain/advance-…
After more than 40 years, a new therapy for CIDP has arrived: EFGARTIGIMOD (VYVGART). In this post, I break down the key findings from the ADHERE trial that led to FDA-approval and share how this breakthrough has changed my clinical practice. thelancet.com/journals/laneu… 1/X
New @NatureMedicine paper: AAV mini-dystrophin gene therapy for Duchenne muscular dystrophy: a phase 1b trial. #DMD tinyurl.com/bdhwrkka
Today is #WorldFSHDDay! Facioscapulohumeral muscular dystrophy (FSHD) is a genetic condition that causes progressive muscle weakening, often starting in the face, shoulders, and upper arms. Join us in raising awareness and supporting research. #WorldFSHDDay 🍊
💙 Volem agrair de tot cor a l’associació #ForçAME per la seva constància recaptant fons amb actes i accions solidàries Estem molt orgullosos de rebre els 15.000 € recaptats aquest 2025. Continuarem treballant per la recerca i l’atenció multidisciplinària de l’AME 🔬
Novel DES mutation presenting with isolated restrictive respiratory failure. Expanding the clinical spectrum elsevier.es/es-revista-neu…
We are pleased to announce a new paper published on a study aimed to characterise a large cohort of paediatric and adult patients with Becker muscular dystrophy (#BMD) to inform clinical care and the development of standards of care guidelines 👏 link.springer.com/content/pdf/10…
New #SkeletalMuscle paper: Contrasting Becker and Duchenne muscular dystrophy serum biomarker candidates by using data independent acquisition LC-MS/MS. tinyurl.com/3e9xkv43
New @NatureComms paper: Complementing muscle regeneration—fibro-adipogenic progenitor and macrophage-mediated repair of elderly human skeletal muscle. tinyurl.com/yvr65vm9
🚀 The national, multicentre study DM1-Hub held its launch event yesterday at IGTP 🎯 The project, led by the GRENBA group, aims to transform research and care for Myotonic Dystrophy Type 1 Read more: bit.ly/launch_DM1Hub #DM1Hub #GRENBA
News: The U.S. FDA granted Platform Technology Designation to SRP-9003, Sarepta’s investigational gene therapy for the treatment of LGMD type 2E/R4. This is one of the first programs to receive the technology designation. Read more at Sarepta.com.
New paper from @GeneticaSantPau team: Translating Muscle RNAseq Into the Clinic for the Diagnosis of Muscle Diseases. pubmed.ncbi.nlm.nih.gov/40413734/ congrats to first author @AlbaSegarraC and rest of the team @IRSantPau @HospitalSantPau @CIBERER @UABBarcelona @AEGHgenetica
Long-term data from Genethon’s GNT0004 Phase 1/2 trial reveal sustained motor function in boys with Duchenne muscular dystrophy. buff.ly/O7gvVfx #MuscularDystrophyNews #MuscularDystrophy
Excited to share our latest preprint: 🧬 “Brogidirsen and Exon 44 Skipping for DMD: Advances and Challenges in RNA-Based Therapy” preprints.org/manuscript/202… Proud of Annie Tang’s excellent work leading this review. #DMD #RNAtherapy #exonskipping #ASO @Preprints_org @UAlberta_FoMD
Ayúdanos🙏 ¿Cómo votar? 1️⃣ Entra en el siguiente enlace: a.cstmapp.com/gallery/992266… 2️⃣ Busca “Proyecto Alpha” (está en la página 3) 3️⃣ Regístrate con tu nombre, apellidos y correo electrónico 4️⃣ Confirma tu voto desde el email que recibirás (¡muy importante este paso!)
Large-scale profiling of antibody reactivity to glycolipids in patients with Guillain-Barré syndrome pubmed.ncbi.nlm.nih.gov/40096525/
United States Trends
- 1. #Worlds2025 39.8K posts
- 2. #TalusLabs N/A
- 3. Doran 16.6K posts
- 4. #T1WIN 26.4K posts
- 5. Sam Houston 1,564 posts
- 6. Boots 29.5K posts
- 7. Oregon State 4,850 posts
- 8. Lubin 5,740 posts
- 9. Faker 31.8K posts
- 10. #GoAvsGo 1,584 posts
- 11. Louisville 14.5K posts
- 12. Keria 10.1K posts
- 13. #T1fighting 3,385 posts
- 14. Miller Moss 1,242 posts
- 15. Emmett Johnson 2,560 posts
- 16. UCLA 7,864 posts
- 17. Oilers 5,267 posts
- 18. Hyan 1,372 posts
- 19. Nuss 5,731 posts
- 20. Frankenstein 126K posts
You might like
-
NeuromuscularBCN - Sant Pau
@NMDSantPau -
JWMDRC
@jwmdrc -
Neurología. Hospital de la Santa Creu i Sant Pau
@neurosantpau -
Sant Pau Ictus
@SantPauIctus -
Unidad de Cefaleas y Neuralgias
@UCNSantPau -
Brain Sant Pau - Unidad de Esclerosis Múltiple
@BrainSantpau -
Daniel Alcolea
@DAlcoleaR -
Marta Caballero
@Marta_caav -
Alejandro Gonzalez Chamorro
@ChamoAGC -
Alba Segarra Casas
@AlbaSegarraC -
Antonio Medina
@amedrodz -
Noemí Morollón
@NMorolln
Something went wrong.
Something went wrong.